GlobeNewswire by notified

PharmaLedger Association Launches Digital Trust Ecosystem in Healthcare

Share

BASEL, Switzerland, March 13, 2023 (GLOBE NEWSWIRE) -- The PharmaLedger Association™ (PLA), a not-for-profit based in Switzerland, announces the endorsement of its 3-year strategic plan to implement and promote a Digital Trust Ecosystem in healthcare (DTE-H) at its Annual General Meeting held in Lucerne, Switzerland on 1 March 2023. The member organizations also confirmed the appointment of eight Directors to its board, delivering on PLA’s core value of “Ecosystem Leadership.”

Representing the diversity of healthcare, PLA’s founding members comprise of large and small pharmaceutical companies, research organizations, patient representative organizations, non-profit organizations, technology, and healthcare service providers. PLA has confirmed its mandate as a pre-competition umbrella organization delivering common and interoperable digital solutions in the areas of Product Trust, Decentralized Clinical Trials, and Supply Chain Traceability.

  • Products & Project: In Q1 2023, PLA will release the first qualified product, electronic Product Information for implementation by its members.
    In Q2 2023, the Association will continue with the development of new products in its innovation xLab, including of a product digital twin, decentralized identities, and verifiable credentials to facilitate visibility, security, traceability, and trust in all areas of healthcare.
  • Governance & Compliance: PLA will leverage its capability to develop, qualify, launch, and maintain products in healthcare’s highly regulated environment by ensuring continuous adherence to antitrust, intellectual property, data privacy, and Computerized System Assurance guidelines.

  • Ecosystem Engagement & Growth: The association will continue to onboard new members and engage with authorities, trade associations and standards development organizations, ensuring growth and financial viability.

  • Platform Technology & Security: PLA will focus on easing adoption of new solutions with its members and users while maintaining the cybersecurity benefits of its architecture.

The formation of PLA and the endorsement of its mission by diverse members of healthcare is a major milestone. This paves the way for delivery of widely trusted blockchain-based platforms with new open-source healthcare solutions to create value for patients and ecosystem stakeholders. PLA is grateful to its 20 founding members and invites all healthcare related organizations to learn more and engage towards the realization of a trusted Healthcare 4.0.

“Blockchain is a team sport. PLA has started with a diverse and strong team of members with a common vision and who believe in real change. With PLA we have the right vehicle, resources, and roadmap to take patients to a better place in healthcare,”Daniel Fritz, Executive Director, PharmaLedger Association.

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

PLA is the result of the successful completion of the PharmaLedger research project, a €22 million, 30-member consortium with 12 large pharma companies and 18 public partners, funded under the European Union (EU) and European Federation of Pharmaceutical Industries and Associations (EFPIA)’s Innovative Health Initiative.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0682572a-b8ac-4b5b-885b-8af008287cff

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release

VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi

Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa

Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release

BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe

Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release

First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann

HiddenA line styled icon from Orion Icon Library.Eye